|
| Status |
Public on Dec 27, 2013 |
| Title |
Androgen and Glucocorticoid stimulation of LREX' cells in vitro |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
The treatment of advanced prostate cancer has been transformed by novel antiandrogen therapies such as enzalutamide. Using the LnCaP/AR xenograft model, we identified induction of glucocorticoid receptor (GR) expression as a common feature of drug resistant tumors. From a resistant xenograft tumor, we derived a GR expressing resistant subline called LREX. In this model, activation of GR and AR activate a similar but distinguishable set of target genes.
|
| |
|
| Overall design |
LREX' cells were cultured in steroid depleted media and then treated for 8 hours with the indicated drugs in biological triplicates.
|
| |
|
| Contributor(s) |
Arora VK, Schenkein E, Sawyers CL |
| Citation(s) |
24315100 |
| |
| Submission date |
Oct 29, 2013 |
| Last update date |
Aug 13, 2018 |
| Contact name |
Vivek Kumar Arora |
| Organization name |
Memorial Sloan Kettering Cancer Center
|
| Department |
HOPP
|
| Lab |
Charles Sawyers
|
| Street address |
1275 York Avenue
|
| City |
New York |
| State/province |
NY |
| ZIP/Postal code |
10065 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL10558 |
Illumina HumanHT-12 V4.0 expression beadchip |
|
| Samples (24)
|
|
| This SubSeries is part of SuperSeries: |
| GSE52169 |
Glucocorticoid Receptor Confers Resistance to Anti-Androgens by Bypassing Androgen Receptor Blockade. |
|
| Relations |
| BioProject |
PRJNA225673 |
Less...
More...